Co-mutated pathways analysis highlights the coordination mechanism in glioblastoma multiforme

Neoplasma

Volumn 61, Issue 4, 2014, Pages 424-432

  Wei, B ^a   Wang, L ^b   Zhao, X L ^a   Jin, Y ^c   Kong, D L ^a   Hu, G Z ^a   Sun, Z G ^a,d  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c Jilin Oil Field General Hospital   (China)

^d INNER MONGOLIA UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

Co mutated pathway pairs; Combined therapy; Gene mutation; Glioblastoma multiforme

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; GENE FREQUENCY; GENE MUTATION; GLIOBLASTOMA; HUMAN; NONSENSE MUTATION; PROTO ONCOGENE; REGULATORY MECHANISM; SCORING SYSTEM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; WNT SIGNALING PATHWAY;

COMPUTATIONAL BIOLOGY; GENE REGULATORY NETWORKS; GLIOBLASTOMA; HUMANS; MUTATION; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84904392220     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_052     Document Type: Article

References (45)

1. VOGELSTEIN B, KINZLER KW. Cancer genes and the pathways they control. Nat Med. 2004; 10: 789-799. http://dx.doi.org/10.1038/nm1087
2. WANG J, ZHANG Y, SHEN X, ZHU J, ZHANG L et al. Finding co-mutated genes and candidate cancer genes in cancer genomes by stratified false discovery rate control. Mol Biosyst. 2011; 7: 1158-1166. http://dx.doi.org/10.1039/c0mb00211a
3. PARSONS DW, JONES S, ZHANG X, LIN JC-H, LEARY RJ et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812. http://dx.doi.org/10.1126/science.1164382
4. Jones S, Zhang X, PARSONS DW, LIN JC-H, LEARY RJ et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Sci Signal. 2008; 321: 1801.
5. BEROUKHIM R, GETZ G, NGHIEMPHU L, BARRETINA J, HSUEH T et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci. 2007; 104: 20007-20012. http://dx.doi.org/10.1073/pnas.0710052104
6. BLEEKER FE, LAMBA S, RODOLFO M, SCARPA A, Leen-Stra S et al. Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Hum Mutat. 2009; 30: E451-E459. http://dx.doi.org/10.1002/humu.20927
7. SJ BLOM T, JONES S, WOOD LD, PARSONS DW, LIN J et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268-274. http://dx.doi.org/10.1126/science.1133427
8. DING L, GETZ G, WHEELER DA, MARDIS ER, MCLELLAN MD et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069-1075. http://dx.doi.org/10.1038/nature07423
9. NIBBE RK, KOYUT RK M, CHANCE MR. An integrativeomics approach to identify functional sub-networks in human colorectal cancer. PLoS Comput Biol. 2010; 6: e1000639. http://dx.doi.org/10.1371/journal.pcbi.1000639
10. KLIJN C, BOT J, ADAMS DJ, REINDERS M, WESSELS L et al. Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach. PLoS Comput Biol. 2010; 6: e1000631. http://dx.doi.org/10.1371/journal.pcbi.1000631
11. MA W, YANG D, GU Y, GUO X, ZHAO W et al. Finding diseasespecific coordinated functions by multi-function genes: insight into the coordination mechanisms in diseases. Genomics. 2009; 94: 94-100. http://dx.doi.org/10.1016/j.ygeno.2009.05.001
12. YEANG C-H, MCCORMICK F, LEVINE A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 2008; 22: 2605-2622. http://dx.doi.org/10.1096/fj.08-108985
13. GU Y, ZHAO W, XIA J, ZHANG Y, WU R et al. Analysis of pathway mutation profiles highlights collaboration between cancer associated superpathways. Hum Mutat. 2011; 32: 1028-1035. http://dx.doi.org/10.1002/humu.21541
14. MANN KM, WARD JM, YEW CCK, KOVOCHICH A, DAWSON DW et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci. 2012; 109: 5934-5941. http://dx.doi.org/10.1073/pnas.1202490109
15. TORKAMANI A, SCHORK NJ. Identification of rare cancer driver mutations by network reconstruction. Genome Res. 2009; 19: 1570-1578. http://dx.doi.org/10.1101/gr.092833.109
16. UREN AG, KOOL J, MATENTZOGLU K, DE RIDDER J, MATTISON J et al. Large-Scale Mutagenesis inp19ARFandp53-Deficient Mice Identifies Cancer Genes and Their Collaborative Networks. Cell. 2008; 133: 727-741. http://dx.doi.org/10.1016/j.cell.2008.03.021
17. GU Y, YANG D, ZOU J, MA W, WU R et al. Systematic interpretation of comutated genes in large-scale cancer mutation profiles. Mol Cancer Ther. 2010; 9: 2186-2195. http://dx.doi.org/10.1158/1535-7163.MCT-10-0022
18. DA WEI HUANG BTS, LEMPICKI RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2008; 4: 44-57. http://dx.doi.org/10.1038/nprot.2008.211
19. OGATA H, GOTO S, SATO K, FUJIBUCHI W, BONO H et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999; 27: 29-34. doi: gkc043 [pii].
20. SUGIMURA H, YAMADA H, KAGEYAMA S, YAMAMURA Y, YOKOTA N et al. Glioblastoma: Germline Mutation of TP53. Tumors of the Central Nervous System, Volume 2. Springer; 2011. p. 31-38.
21. OHGAKI H, DESSEN P, JOURDE B, HORSTMANN S, NISHIKAWA T et al. Genetic Pathways to Glioblastoma A Population-Based Study. Cancer Res. 2004; 64: 6892-6899. http://dx.doi.org/10.1158/0008-5472.CAN-04-1337
22. BONAVIA R, MUKASA A, NARITA Y, SAH DW, VANDENBERG S et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24: 1731-1745. http://dx.doi.org/10.1101/gad.1890510
23. CHO J, PASTORINO S, ZENG Q, XU X, JOHNSON W et al. Glioblastoma-derived epidermal growth factor receptor carboxylterminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011; 71: 7587-7596. http://dx.doi.org/10.1158/0008-5472.CAN-11-0821
24. WANG SI, PUC J, LI J, BRUCE JN, CAIRNS P et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997; 57: 4183-4186.
25. SMITH JS, TACHIBANA I, PASSE SM, HUNTLEY BK, BORELL TJ et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001; 93: 1246-1256. http://dx.doi.org/10.1093/jnci/93.16.1246
26. KRAUS JA, GLESMANN N, BECK M, KREX D, Klock-Gether T et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol. 2000; 48: 89-94. http://dx.doi.org/10.1023/A:1006402614838
27. GENG H, HSIEH P. Molecular Mechanisms and Functions of DNA Mismatch Repair. DNA Alterations in Lynch Syndrome. Springer; 2013. p. 25-45. http://dx.doi.org/10.1007/978-94-007-6597-9_2
28. HOEIJMAKERS JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001; 411: 366-374. http://dx.doi.org/10.1038/35077232
29. FELSBERG J, THON N, EIGENBROD S, HENTSCHEL B, SABEL MC et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011; 129: 659-670. http://dx.doi.org/10.1002/ijc.26083
30. TANG Y, HE W, WEI Y, QU Z, ZENG J et al. Screening Key Genes and Pathways in Glioma Based on Gene Set Enrichment Analysis and Meta-analysis. J Mol Neurosci. 2013: 1-9.
31. SER O NV, DELFINO KR, SOUTHEY BR, BEEVER JE, Rodriguez-Zas SL. Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics. 2011; 4: 49. http://dx.doi.org/10.1186/1755-8794-4-49
32. DE GROOT J, SONTHEIMER H. Glutamate and the biology of gliomas. Glia. 2011; 59: 1181-1189. http://dx.doi.org/10.1002/glia.21113
33. EICHHORN PJ, ROD N L, Lez-Junc A, DIRAC A, GILI M et al. USP15 stabilizes TGF-[beta] receptor I and promotes oncogenesis through the activation of TGF-[beta] signaling in glioblastoma. Nat Med. 2012: 429-435.
34. KANU OO, HUGHES B, DI C, LIN N, FU J et al. Glioblastoma multiforme oncogenomics and signaling pathways. Clinical medicine Oncology. 2009; 3: 39.
35. JOHNSON MD, JENNINGS MT, GOLD LI, MOSES HL. Transforming growth factor-β in neural embryogenesis and neoplasia. Hum Pathol. 1993; 24: 457-462. http://dx.doi.org/10.1016/0046-8177(93)90156-B
36. PAULUS W, BAUR I, HUETTNER C, SCHMAUBER B, ROGGENDORF W et al.Effects of Transforming Growth Factor-[beta] 1 on Collagen Synthesis, Integrin Expression, Adhesion an Invasion of Glioma Cells. Journal of Neuropathology & Experimental Neurology. 1995; 54: 236-244. http://dx.doi.org/10.1097/00005072-199503000-00010
37. GAO Y, VASILYEV DV, GONCALVES MB, HOWELL FV, HOBBS C et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knockout mice. J Neurosci. 2010; 30: 2017-2024. http://dx.doi.org/10.1523/JNEUROSCI.5693-09.2010
38. JACOBSSON SO, WALLIN T, FOWLER CJ. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther. 2001; 299: 951-959.
39. VELASCO G, Galve-Roperh I, SNCHEZ C, BL ZQUEZ C, GUZM N M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology. 2004; 47: 315-323. http://dx.doi.org/10.1016/j.neuropharm.2004.04.016
40. SCHLEY M, ST NDER S, KERNER J, VAJKOCZY P, SCH PFER G et al. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull. 2009; 79: 333-337. http://dx.doi.org/10.1016/j.brainresbull.2009.01.011
41. GARDNER B, ZU LX, SHARMA S, LIU Q, MAKRIYANNIS A et al. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-β. Biochem Biophys Res Commun. 2002; 290: 91-96. http://dx.doi.org/10.1006/bbrc.2001.6179
42. CHEN X, ZANG W, XUE F, SHEN Z, ZHANG Q. Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma. Neurol Sci. 2012: 1-5.
43. YAMAGUCHI H, CONDEELIS J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2007; 1773: 642-652. http://dx.doi.org/10.1016/j.bbamcr.2006.07.001
44. STEGH AH, DEPINHO RA. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle. 2011; 10: 33-38. http://dx.doi.org/10.4161/cc.10.1.14365
45. ZOHRABIAN VM, FORZANI B, CHAU Z, MURALI R, Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009; 29: 119-123.